Acitretin

CAS No. 55079-83-9

Acitretin( all-trans Acitretin | Ro 10-1670 | Ro 10-1670/000 )

Catalog No. M14992 CAS No. 55079-83-9

Acitretin(Ro 10-1670) is a second-generation, systemic retinoid that has been used in the treatment of psoriasis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG 100 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Acitretin
  • Note
    Research use only, not for human use.
  • Brief Description
    Acitretin(Ro 10-1670) is a second-generation, systemic retinoid that has been used in the treatment of psoriasis.
  • Description
    Acitretin(Ro 10-1670) is a second-generation, systemic retinoid that has been used in the treatment of psoriasis.(In Vivo):Acitretin (10 mg/kg; i.p. for 7 days) increases IL-6 in the central nervous system of Alzheimer’s disease model mice.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    all-trans Acitretin | Ro 10-1670 | Ro 10-1670/000
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Retinoid Receptor
  • Recptor
    RAR| RXR
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    55079-83-9
  • Formula Weight
    326.43
  • Molecular Formula
    C21H26O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 20 mg/mL (61.26 mM)
  • SMILES
    CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
  • Chemical Name
    (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Orfanos CE, et al. Drugs. 1997 Mar;53(3):358-88.
molnova catalog
related products
  • KCL-286

    KCL-286 is an orally available and potent retinoic acid receptor beta agonist for the amelioration of spinal cord injury (SCI).

  • Bexarotene

    Bexarotene is a retinoid specifically selective for retinoid X receptors, used as an oral antineoplastic agent in the treatment of cutaneous T-cell lymphoma.

  • PA452

    PA452 is a retinoic X receptor (RXR) specific antagonist. PA452 suppresses the effect of Retinoic acid (RA) on Th1/Th2 development.